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Methods: Patients with peripheral tumors ≤ 5 cm are treated with 
SBRT without body frame to 54 Gy in 3 fractions within 8-10 days. 
For treatment planning, a 4DCT reference scan is acquired representing 
the patients anatomy over the breathing cycle. From this 4D dataset, a 
single 3D frame is extracted with the tumor and surrounding anatomy 
in their time averaged mean position. The Planning-Target-Volume 
(PTV)-margins depend on the patient speciﬁc tumor amplitude. Or-
gans-at-risk (OAR) are delineated and automatically expanded by 1 cm 
to validate that corrections up to 1 cm during treatment delivery can be 
safely executed without violating ﬁxed dose constraints. Before each 
treatment fraction, the linac integrated CBCT scanner is used to acquire 
a new 4D data set (Figure 1a). A local rigid registration technique is 
used to measure the tumor trajectory after which the time averaged 
tumor misalignment is calculated and corrected with a couch shift. At 
the end of the treatment fraction another 4D-CBCT scan is acquired to 
determine intrafraction stability. 
Results: So far 34 patients have been treated with SBRT in our institu-
tion. Residual treatment delivery inaccuracies were analyzed for the 
ﬁrst 20 patients. Based on these results, the required PTV-margin were 
calculated to account for delineation uncertainties (2 mm SD in each 
direction), breathing motion, residual setup errors and intrafraction 
baseline variation (both ≤ 2 mm (1 SD) systematic and random) as 
shown in Figure 1b. For example at a 1 cm tumor amplitude, a total 
margin of only 0.7 cm is required. Compared to a bony anatomy driven 
correction protocol combined with an Internal-Target-Volume (ITV) 
approach to account for respiratory motion this is a 49% reduction. 
For all patients, tumor-to-bony anatomy discrepancies never exceeded 
1 cm and post treatment validation scans did not show unacceptable 
deviations.
Conclusion: SBRT without body frame can be safely administered us-
ing 4D-CBCT guidance. Even with considerable breathing motion the 
PTV-margins can safely be kept relatively small allowing patients with 
larger tumor volumes to beneﬁt from the advantages of SBRT.
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Background: Platinum-based CT-RT improves survival in stage III 
NSCLC compared to RT, although with increased toxicity. Drug doses 
in most concurrent schemes are suboptimal for systemic activity, and 
full dose induction or consolidation CT appears advantageous. Some 
trials had suggested that induction CT followed by concurrent RT was 
not superior to concurrent RT followed by consolidation CT. Docetaxel 
(D) is active in NSCLC, has radiosensitising effect and is promising 
when given as consolidation agent. 
Aim: Randomised phase 2 trial comparing the toxicity/safety and 
efﬁcacy of CT followed by CT-RT (IND) vs. CT-RT followed by CT 
(CON).
Methods: Eligible pts had unresectable stage III NSCLC and WHO 
PS 0-1, weight loss ≤10%, adequate renal, pulmonary, haematologi-
cal and hepatic function. Induction and consolidation CT consisted of 
D 75 mg/m2 on d1 and cisplatin (C) 40 mg/m2 on d1&2, both q3 wks 
for 2 cycles. CT-RT consisted of D 20 mg/m2 and C 20 mg/m2 both 
given on d1 weekly for 6 wks, concurrent with 66 Gy (2 Gy/d, 5 d/w 
for 6.5 wks). Toxicity was reduced using the following approaches: 1. 
Involved ﬁelds using 3D treatment planning; 2: exclusion of pts with 
V20 values >35 Gy from immediate concurrent CT-RT by cross-over 
to IND and treatment to a post-CT tumor volume. Toxicity/response 
was evaluated according to NCI-CTC/RECIST. With a type 1 error 
of 0.2, a power of 0.8 and allowing for 15% cross-over or ineligibil-
ity, a 70-pts sample size is needed to conﬁdently exclude a grade 3-4 
oesophageal toxicity rate of >25% in either arm. Toxicity and response 
were based upon actual treatment received; outcome is estimated in the 
ITT population.
Results: 70 patients with the following characteristics were enrolled: 
IND: 36/CON: 34; male (%): IND 75/CON 91; median age 61 y; 
squamous ca (%): IND 31; CON: 50; IIIB(%): IND 44/CON 68; PTV 
(cc): IND 288/CON 283. 5 pts switched from CON to IND. Treatment, 
response and toxicity data according to actual treatment received are in 
the table. ITT 1-year overall and progression free survival (PFS) rates 
(± 95% CI) are 56% ± 16% and 36% ± 16% for IND and 65% ± 17% 
and 53% ± 17% for CON (p =0.8 and 0.3)
Conclusions: Both IND and CON approaches have similar treatment 
intensity and duration, similar esophageal toxicity rates and comparable 
response rates. CON results in a trend towards a better PFS at the cost 
of a higher haematological toxicity. 
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Figure 1: a) Coronal slices of three frames of a 4D-CBCT scan acquired just prior to SBRT 
treatment. Despite some artifacts, tumor motion and accurate alignment can be easily 
verified.  b) Cranial-caudal GTV-to-PTV margin (no CTV margin used) required to account 
for delineation uncertainties, breathing motion, residual setup error and intrafraction 
variability as a function of tumor peak-to-peak amplitude: using 4D-CBCT guidance 
compared to a bony anatomy driven protocol combined with an ITV approach. Even at 
large tumor amplitudes margins are relatively small due to accurate guidance, shallow
penumbra in lung and dose prescription to relative low iso-doses (typically 70% to 80%).
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Table (according to actual treatment 
received)
IND (N= 41) CON (N= 29) p
Median RDI docetaxel (%) 99 93 NS
Median RDI cisplatin (%) 99 96 NS
Median RDI radiotherapy (%) 100 100 NS
Overall treatment time (days) 87 72 NS
Grade 3/4 neutropenia / 
febrile neutropenia (%) 22/5 41/17 0.08/0.09
Gr 3/4 esophagitis/pneumonitis (%) 34/10 28/10 0.56/0.96
Gr 3/4 nausea/vomiting (%) 5 14 0.18
Deaths during and within 30 d of treatment 0 2 0.09
Best response at end of treatment (%) 68 83 0.17
B5-07 NSCLC: New Paradigm in Radiation Therapy, Tue, 13:45 - 15:30
The effect of NQO1 polymorphisms on prognosis of non-small cell 
lung cancer after postoperative radiation therapy
Song, Si Yeol1 Choi, Eun Kyung1 Lee, Jung Shin2 Park, Heon Joo3 Lee, 
Sang-Wook1 Park, Seung Il4 Kim, Dong-Kwan4 Kim, Sang-We2 Lee, 
Dae Ho2 Lee, Yu Sun1 
1 Dept. of Radiation Oncology, Asan Medical Center, College of Medi-
cine, University of Ulsan, Seoul, Korea 2 Dept. of Medical Oncology, 
Asan Medical Center, College of Medicine, University of Ulsan, Seoul, 
Korea 3 Dept. of Microbiology, College of Medicine, Inha University, 
Incheon, Korea 4 Dept. of Thoracic Surgery, Asan Medical Center, Col-
lege of Medicine, University of Ulsan, Seoul, Korea 
Purpose: NQO1 is an enzyme that catalyzes the two-electron reduction 
of the more toxic quinone to less toxic hydroquinone. It is known that 
NQO1 may decrease the risk of cancer development in normal human 
tissue, and NQO1 polymorphism affect on the treatment outcome after 
chemotherapy in lung cancer. We investigated the effect of NQO1 
polymorphism on radiation therapy through the difference of survival 
outcome by NQO1 different genotypes in non-small cell lung cancer 
(NSCLC) patients treated with surgery followed by postoperative radia-
tion therapy.
Methods: One hundred and ﬁfty-two patients (Male: 116, Female: 
36) who were histologically proven NSCLC and treated with surgery 
and postoperative radiation therapy from Jan 2000 to Aug 2005 were 
analyzed. We determined NQO1 genotypes from peripheral blood of 
patients. NQO1 genotypes were classiﬁed as three groups, and each 
genotype had different enzymatic activities; C/C is the wild type with 
normal activity, C/T is the heterozygous type with decreased activity, 
and T/T is the homozygous mutation with no enzymatic activity. There-
after, we analyzed the correlation between NQO1 genotypes and the 
survival outcome after surgery and postoperative radiation therapy. For 
the authenticity of genotype from peripheral blood, genotypic analysis 
directly from tumor tissue was performed.
Results: Numbers of patients in each NQO1 genotype were 41 patients 
for C/C, 83 patients for C/T, and 28 patients for T/T. Patients character-
istics with sex, age, clinical stage, pathology, and combined chemo-
therapy were not different between genotypic groups. Median fol-
low-up period was 19.7 months. NQO1 genotype had an effect on the 
actuarial loco-regional control and survival. Patients expressing C/C 
and C/T genotype with NQO1 enzymatic activity had a signiﬁcantly 
longer loco-regional progression free survival (89.2% vs. 68.3% at 2yr) 
and overall survival (90.2% vs. 70.6% at 2yr) than patients expressing 
T/T genotype (p=0.034). Genotypic analysis from tumor tissue was 
performed in only eighteen patients. There was accordance in sixteen 
patients between the genotype from peripheral blood and that directly 
from tumor tissue, and the other two patients with C/C genotype in 
blood expressed C/T in tumor tissue.
Conclusions: NQO1 polymorphisms affected on treatment results 
in NSCLC patients treated with surgery and postoperative radiation 
therapy. NQO1 could be a useful prognostic factor for NSCCL after 
radiation therapy, although the further study with more patients and 
long-term follow-up should be promised.
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Introduction: Lung cancer is an increasing problem in developing 
countries, where access to medical resources may be limited. It is 
crucial that care in these settings makes most effective and cost effec-
tive use of those resources, based on good evidence. Clinical guideline 
recommendations from developed countries are not likely to be always 
(or ever) appropriate and so a different approach is needed.
Methods: An international panel, with a special interest in lung cancer, 
was invited to a meeting organised by the IAEA in March 2006, at 
which the main approaches were drafted. Reference was made to recent 
English language evidence-based clinical guidelines and to other recent 
systematic reviews, meta-analyses and research. Drafts were then circu-
lated sequentially around the group members, a telephone conference 
held and a ﬁnal version approved. We assumed that baseline resources 
for diagnosis (including CT scanning), radical surgery, radiotherapy 
(RT) with at least 60Co and 2D planning and IV cisplatin-based combi-
nation chemotherapy (CT) would be available. Tables were constructed 
that showed a baseline standard treatment for different patient groups 
and the additional beneﬁts, risks and resource use from additional 
treatment options. Accompanying text summarised the evidence and 
justiﬁcation for these options.
Results: Six tables were devised entitled:
1. Options for patients with limited disease SCLC and good prognosis
2. Options for patients with operable NSCLC
3. RT options for patients with medically inoperable NSCLC (Stage I 
and II)
4. Options for patients with inoperable ‘small’ volume NSCLC (‘Fa-
vourable’ Stage III)
5. Options for palliative thoracic RT
